Medline $MDLN Stake Decreased by Machina Capital S.A.S.

Machina Capital S.A.S. cut its holdings in Medline (NASDAQ:MDLN – Free Report) by 46.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,677 shares of the company’s stock after selling 12,986 shares during the period. Machina Capital S.A.S.’s holdings in Medline were worth $509,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC lifted its position in Medline by 68.3% during the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after purchasing an additional 254 shares in the last quarter. Reyes Financial Architecture Inc. purchased a new stake in Medline in the third quarter worth about $30,000. NewEdge Advisors LLC increased its position in Medline by 100.0% in the second quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock worth $37,000 after buying an additional 475 shares in the last quarter. Allworth Financial LP raised its stake in shares of Medline by 86.2% in the second quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock worth $41,000 after buying an additional 487 shares during the period. Finally, Assetmark Inc. bought a new position in shares of Medline during the 1st quarter valued at approximately $62,000.

Medline Stock Performance

Shares of NASDAQ MDLN opened at $39.47 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.51 and a current ratio of 4.04. The company has a market cap of $51.92 billion and a P/E ratio of 89.71. The firm’s fifty day moving average is $35.28 and its two-hundred day moving average is $39.37. Medline has a 52-week low of $31.37 and a 52-week high of $50.88.

Medline (NASDAQ:MDLN – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. Medline had a return on equity of 8.21% and a net margin of 1.84%. The company had revenue of $7.86 billion for the quarter. As a group, analysts anticipate that Medline will post 1.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on MDLN shares. UBS Group raised their target price on shares of Medline from $43.00 to $49.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. JPMorgan Chase & Co. decreased their price objective on shares of Medline from $53.00 to $46.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 12th. Robert W. Baird set a $42.00 target price on shares of Medline in a research note on Thursday, August 6th. TD Cowen dropped their target price on shares of Medline from $53.00 to $45.00 and set a “buy” rating for the company in a report on Monday, August 10th. Finally, BTIG Research reiterated a “buy” rating and issued a $55.00 price target on shares of Medline in a research note on Thursday, November 5th. Twenty-three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Medline currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.08.

Read Our Latest Report on Medline

Insider Buying and Selling at Medline

In related news, major shareholder Private Ltd Gic sold 2,570,999 shares of the business’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $35.35, for a total value of $90,884,814.65. Following the sale, the insider owned 20,231,483 shares in the company, valued at approximately $715,182,924.05. The trade was a 11.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 6,348,676 shares of company stock valued at $224,525,137 over the last ninety days. Company insiders own 0.81% of the company’s stock.

Medline Profile

(Free Report)

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.

See Also

Institutional Ownership by Quarter for Medline (NASDAQ:MDLN)

Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.